



## Lyell Immunopharma to Participate in Upcoming Investor Conferences

August 31, 2023 at 4:05 PM EDT

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the following upcoming healthcare conferences:

- **Morgan Stanley 21st Annual Global Healthcare Conference**
  - Monday, September 11, 4:55 p.m. ET
- **H.C. Wainwright 25th Annual Global Investment Conference**
  - Tuesday, September 12<sup>th</sup>, 9:00 a.m. ET
- **2023 Cantor Global Healthcare Conference**
  - Wednesday, September 27<sup>th</sup> at 3:35 p.m. ET

Live webcasts of the presentations can be accessed through the investor relations section of the Company's website at [www.lyell.com](http://www.lyell.com). Following the live presentations, a replay of the webcast will be available on the Company's website for 90 days following the presentation date.

### About Lyell Immunopharma, Inc.

Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. Lyell is currently enrolling a Phase 1 clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase 1 clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop new medicines with improved durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington. To learn more, please visit [www.lyell.com](http://www.lyell.com).

### Contact:

Ellen Rose

Senior Vice President, Communications and Investor Relations

[erose@lyell.com](mailto:erose@lyell.com)